Morán, AlbertoGarcía-Aranda, CarmenDíaz-López, AntonioIniesta Serrano, María PilarJuan Chocano, María Del Carmen DeSánchez Pernaute, AndrésTorres García, Antonio JoséDíaz-Rubio García, EduardoBalibrea Cantero, José LuisBenito De Las Heras, Manuel R.2025-01-272025-01-272005Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez- Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL, Benito M. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005 Jan;13(1):115-20. PMID: 15583811.1021-335X10.3892/or.13.1.115https://hdl.handle.net/20.500.14352/116227The main aim of this study was to evaluate the clinical relevance of Gelatinases in colorectal cancer (CRC). Ninety-five CRCs and their paired normal tissues were investigated to detect total levels of MMP-9, MMP-2, and the tissue inhibitors TIMP-1 and TIMP-2. Also, pro-MMP and MMP activity, and potential associations with clinical parameters were estimated. MMP-9, MMP-2 and TIMP-1 levels were greater in CRCs than in normal tissues, differences being significant for MMP-9 and TIMP-1. However, TIMP-2 showed significantly lower levels in tumour samples. Moreover, significant differences in the state of activation between gelatinases were found. TIMP-1 low levels were significantly associated with poor clinical outcome of patients. According to these data, different roles have to be attributed to MMP-2 and MMP-9 in CRC progression. Moreover, TIMP-1 level evaluation emerges as the main prognostic factor in relation to Gelatinases A and B activity in CRC.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal article1791-2431https://doi.org/10.3892/or.13.1.115https://www.spandidos-publications.com/orhttps://pubmed.ncbi.nlm.nih.gov/15583811/restricted access616-006.04cáncer de colónAdenocarcinomaMetaloproteinasa de matriz 2Ciencias Biomédicas32 Ciencias Médicas